207 related articles for article (PubMed ID: 16407611)
21. Current overview of angiogenesis inhibitors.
Ellis LM
Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
[No Abstract] [Full Text] [Related]
22. Epidermal growth factor inhibition in solid tumours.
Ganti AK; Potti A
Expert Opin Biol Ther; 2005 Sep; 5(9):1165-74. PubMed ID: 16120047
[TBL] [Abstract][Full Text] [Related]
23. A Combinatorial Investigation of the Response to Anti-angiogenic Therapy in Breast Cancer: New Strategies for Patient Selection and Opportunities for Reconsidering Anti-VEGF, Anti-PI3K and Checkpoint Inhibition.
Labanca V; Bertolini F
EBioMedicine; 2016 Aug; 10():13-4. PubMed ID: 27506898
[No Abstract] [Full Text] [Related]
24. Targeting the ERBB family in cancer: couples therapy.
Tebbutt N; Pedersen MW; Johns TG
Nat Rev Cancer; 2013 Sep; 13(9):663-73. PubMed ID: 23949426
[TBL] [Abstract][Full Text] [Related]
25. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Ruzzo A; Graziano F; Canestrari E; Magnani M
Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
[TBL] [Abstract][Full Text] [Related]
26. Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.
Kim GP; Grothey A
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S89-97. PubMed ID: 16336754
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy.
Ciardiello F; De Vita F
Prog Drug Res; 2005; 63():93-114. PubMed ID: 16265878
[No Abstract] [Full Text] [Related]
28. EGFR/HER-targeted therapeutics in ovarian cancer.
Wilken JA; Badri T; Cross S; Raji R; Santin AD; Schwartz P; Branscum AJ; Baron AT; Sakhitab AI; Maihle NJ
Future Med Chem; 2012 Mar; 4(4):447-69. PubMed ID: 22416774
[TBL] [Abstract][Full Text] [Related]
29. Biological agents versus chemotherapy in the treatment of colorectal cancer.
Eng C; Shalan N
Expert Opin Pharmacother; 2006 Jul; 7(10):1251-71. PubMed ID: 16805714
[TBL] [Abstract][Full Text] [Related]
30. The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics.
Sun GC; Yang X; Yu Y; Zhao DW
Anticancer Agents Med Chem; 2015; 15(7):869-80. PubMed ID: 25783965
[TBL] [Abstract][Full Text] [Related]
31. Targeting EGFR in pancreatic cancer treatment.
Troiani T; Martinelli E; Capasso A; Morgillo F; Orditura M; De Vita F; Ciardiello F
Curr Drug Targets; 2012 Jun; 13(6):802-10. PubMed ID: 22458527
[TBL] [Abstract][Full Text] [Related]
32. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
Machiels JP; Schmitz S
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
[TBL] [Abstract][Full Text] [Related]
33. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer.
Winder T; Lenz HJ
Gastroenterology; 2010 Jun; 138(6):2163-76. PubMed ID: 20420953
[TBL] [Abstract][Full Text] [Related]
34. Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis.
Cepero V; Sierra JR; Giordano S
Curr Pharm Des; 2010; 16(12):1396-409. PubMed ID: 20166985
[TBL] [Abstract][Full Text] [Related]
35. New Molecular Targets of Anticancer Therapy - Current Status and Perspectives.
Zajac M; Muszalska I; Jelinska A
Curr Med Chem; 2016; 23(37):4176-4220. PubMed ID: 27528054
[TBL] [Abstract][Full Text] [Related]
36. Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.
Sartore-Bianchi A; Siena S
Handb Exp Pharmacol; 2018; 249():145-159. PubMed ID: 28382467
[TBL] [Abstract][Full Text] [Related]
37. Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours.
Elez E; Macarulla T; Tabernero J
Ann Oncol; 2008 Sep; 19 Suppl 7():vii146-52. PubMed ID: 18790937
[No Abstract] [Full Text] [Related]
38. Targeted anti-cancer therapy in the elderly.
Gonsalves W; Ganti AK
Crit Rev Oncol Hematol; 2011 Jun; 78(3):227-42. PubMed ID: 20599391
[TBL] [Abstract][Full Text] [Related]
39. [Recent Developments Towards Molecularly Targeted Therapy of Head and Neck Cancer].
Strieth S; Ernst BP
Laryngorhinootologie; 2017 Mar; 96(3):185-198. PubMed ID: 28420025
[No Abstract] [Full Text] [Related]
40. Molecular targeted therapies for pancreatic cancer.
Borja-Cacho D; Jensen EH; Saluja AK; Buchsbaum DJ; Vickers SM
Am J Surg; 2008 Sep; 196(3):430-41. PubMed ID: 18718222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]